Lantern Pharma Launches Phase 2 Clinical Trial iPhone App for Never Smokers

Lantern has launched a first of its kind, patient- focused, iPhone app for our Phase 2  Clinical Trial for Never Smokers with advanced non-small cancer lung cancer (NSCLC), the Harmonic™ trial.

The US Centers for Disease Control (CDC) defines a never smoker as an adult who has never smoked or has smoked less than 100 cigarettes in his or her lifetime. A never smoker can still develop NSCLC, which is clinically and genetically different from NSCLC in smokers. Harmonic™ is a clinical trial that is evaluating the overall and progression-free survival of never smoker patients with relapsed advanced NSCLC after treatment with the investigational new drug LP-300 in combination with chemotherapy.